% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Berclaz:299477,
      author       = {L. M. Berclaz$^*$ and V. Jurinovic and A. Burkhard-Meier
                      and S. Abdel-Rahman and M. Albertsmeier and A. Klein and H.
                      R. Dürr and N.-S. Schmidt-Hegemann and T. Knösel and W. G.
                      Kunz and E. Stutz and M. von Bergwelt-Baildon$^*$ and D. Di
                      Gioia and L. H. Lindner},
      title        = {{D}oxorubicin {P}lus {D}acarbazine {V}ersus {D}oxorubicin
                      {P}lus {I}fosfamide in {C}ombination {W}ith {R}egional
                      {H}yperthermia in {P}atients {W}ith {A}dvanced
                      {L}eiomyosarcoma: {A} {P}ropensity {S}core-{M}atched
                      {A}nalysis.},
      journal      = {Cancer medicine},
      volume       = {14},
      number       = {4},
      issn         = {2045-7634},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2025-00437},
      pages        = {e70655},
      year         = {2025},
      abstract     = {Dacarbazine is currently considered the better combination
                      partner for doxorubicin compared to ifosfamide for the
                      treatment of leiomyosarcoma (LMS). Regional hyperthermia
                      (RHT) combined with neoadjuvant chemotherapy has been shown
                      to improve survival in patients with locally advanced
                      high-risk STS. We sought to evaluate the role of doxorubicin
                      and dacarbazine (AD) versus doxorubicin and ifosfamide (AI)
                      in combination with RHT in patients with LMS.Patients with
                      locally advanced high-grade LMS, including limited
                      metastases, eligible for RHT and first-line treatment with
                      either AI + RHT or AD + RHT between 2014 and 2022 were
                      retrospectively evaluated. Endpoints were progression-free
                      survival (PFS) and overall survival (OS). Patients were
                      matched using propensity scores, which were estimated with a
                      logistic regression model accounting for tumor site,
                      presence of metastasis, surgery, and radiotherapy.A total of
                      105 patients were included in this study, of which 101 were
                      included in the propensity score-matched cohort. In the
                      matched cohort, treatment with AD + RHT was associated with
                      a significantly improved PFS (HR 0.32, $95\%$ CI 0.13-0.74,
                      p = 0.0081). Multivariable analysis revealed several
                      significant predictors of PFS, including treatment with AD +
                      RHT (HR 0.42, $95\%$ CI 0.19-0.92, p = 0.031).Treatment with
                      AD + RHT showed improved PFS and better treatment
                      tolerability compared to AI + RHT. Our results support the
                      use of AD instead of AI for the treatment of patients with
                      LMS in combination with RHT.},
      keywords     = {Humans / Male / Female / Doxorubicin: administration $\&$
                      dosage / Doxorubicin: therapeutic use / Ifosfamide:
                      administration $\&$ dosage / Ifosfamide: therapeutic use /
                      Middle Aged / Leiomyosarcoma: drug therapy / Leiomyosarcoma:
                      therapy / Leiomyosarcoma: pathology / Leiomyosarcoma:
                      mortality / Propensity Score / Antineoplastic Combined
                      Chemotherapy Protocols: therapeutic use / Antineoplastic
                      Combined Chemotherapy Protocols: adverse effects /
                      Retrospective Studies / Aged / Dacarbazine: administration
                      $\&$ dosage / Dacarbazine: therapeutic use / Hyperthermia,
                      Induced: methods / Adult / Progression-Free Survival /
                      Combined Modality Therapy / chemotherapy (Other) /
                      leiomyosarcoma (Other) / regional hyperthermia (Other) /
                      soft tissue sarcoma (Other) / Doxorubicin (NLM Chemicals) /
                      Ifosfamide (NLM Chemicals) / Dacarbazine (NLM Chemicals)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40007213},
      doi          = {10.1002/cam4.70655},
      url          = {https://inrepo02.dkfz.de/record/299477},
}